65,437 trials
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26 — 85.19; 65.45; -26.60; -20.52 units on a scale
Kidney Cancer
Primary: Overall Response Rate (ORR) of Patients Treated at MTD/Phase II Dose Level — 13 percentage of evaluable patients
Contrast Enhanced Computed Tomography
Primary: Acceptable Image Quality — 100; 100; 100 percentage of participants
Pharmacokinetics
Primary: AUC (0-inf) — 126.47; 223.63 h*pg/mL
Orthostatic Hypertension
Primary: Blood Pressure (Systolic) — 156; 158; 179; 148 mm Hg
Dysphagia
Primary: The Change From Baseline and Cut Point VFSS in Velocity of Displacement of Hyoid Bone at 1 to 3 Months — 0.8; -0.4 cm/s
Type 2 Diabetes Mellitus
Primary: Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c) — -0.434; -0.587; 0.091 Percent of glycosylated hemoglobin — p=<0.001
Autistic Disorder
Primary: Rate of Recruitment — 2.1; 2.1 months/participant at 1 site
End Stage Renal Disease
Primary: The Percent Change From Baseline in ESA Dose Required to Maintain Hemoglobin in the Target Range, Adjusted for Hgb. — 4.9; 39.8 Percent change — p=<0.05
Autistic Disorder · Asperger Syndrome · Autism Spectrum Disorder
Primary: Change From Baseline in Aberrant Behavior Checklist-Irritability at 12 Weeks — 7.6; -0.6 units on a scale
Renal Transplant Rejection
Primary: Change in Biopsy Cell Densities From Baseline to Follow-up — -164; -122.5; -129.4; 30.4 cells/mm^3 — p=0.25
Metastatic Melanoma
Primary: Progression-free Survival (PFS) — 4.04 Months
Coronary Artery Disease
Primary: In-Stent Late Lumen Loss — 0.27; 0.58 mm
Influenza
Primary: Haemagglutination Inhibition (HI) Antibody Titers for the A/Turkey/Turkey/01/2005 (H5N1) Vaccine Strain. — 737.6; 24.7 Titer
Disease Susceptibility
Primary: Clopidogrel Resistance, Defined by P2Y12 Reaction Units (PRU)Value >230 — 30; 18 Number of Patients with PRU>230 — p==0.02